Cinqair Approval History
- FDA approved: Yes (First approved March 23rd, 2016)
- Brand name: Cinqair
- Generic name: reslizumab
- Dosage form: Injection
- Company: Teva Pharmaceuticals USA, Inc.
- Treatment for: Asthma
Cinqair (reslizumab) is an interleukin 5 antagonist monoclonal antibody (IgG4 kappa) indicated for add-on maintenance treatment of patients with eosinophilic asthma.
The FDA approval of Cinqair was based on efficacy and safety data from five placebo-controlled studies that included 1,028 asthma patients. In the three Phase III studies, Cinqair was associated with reduction in asthma attacks of up to 59% as well as a significant improvement in lung function, symptoms, and asthma-related quality of life.
Cinqair is administered via intravenous infusion every four weeks in a clinical setting prepared to manage anaphylaxic reactions. The most common side effect reported during clinical trials was oropharyngeal pain.
Teva Pharmaceutical Industries Ltd. accessed March 23, 2016
Development History and FDA Approval Process for Cinqair
|Mar 23, 2016||FDA Approves Cinqair (reslizumab) to Treat Severe Asthma|
|Dec 10, 2015||FDA Advisory Committee Recommends Approval of Teva’s Asthma Biologic Reslizumab|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.